comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-23 10:37:03 - browse：48

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Will an HIV vaccine ever be a reality?

WSS

Why don't Americans have at

Flu, Covid vaccination rates decline, new survey data show

Study gives hint on South Asians’ higher risk of cardiovascular disease

Flu, Covid vaccination rates decline, new survey data show

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

IVG is promising — but it won’t replace IVF quite yet

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

What does generative AI mean for health care? We asked experts

European officials brace for rough respiratory virus season

Heart attack and stroke risk calculators need revising

The United States is paying nearly triple for new Covid vaccines

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why don't Americans have at

At least 13 dead in Texas as scorching temps continue

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Drug repurposing or repositioning? The language matters

Medicare innovation center doesn’t save money, experts say

hotspot

Why Eli Lilly’s earnings didn’t quite live up to the hype

AMAs digital advisors table RPM coding reform proposal, again

Too many hospitalized Covid

Study points to new risk in gene therapy death of Terry Horgan

STAT Boddities: What happens to the brain when we get scared?

Having children helps parents live longer, especially after age 80

leisure time

focus

hotspot

explore